ELAN Elanco Animal Health Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1739104 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.1%
TTM net income YoY-508.3%
TTM EPS YoY-528.6%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—
Margins
Gross margin56.2%
Operating margin—
Net margin-2.9%
FCF margin7.9%
EBITDA margin—
Returns
ROE-2.2%
ROA-1.1%
ROIC (approx.)—
Asset turnover0.38x
Leverage & solvency
Liabilities / assets50.3%
Debt / equity0.56x
Current ratio2.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.18x
Accruals ratio-5.7%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.26B | $1.37B | $1.37B | $1.14B | $1.14B | $1.24B | $1.19B | $1.02B |
| Cost of revenue | $545.00M | $570.00M | $586.00M | $555.00M | $530.00M | $528.00M | $509.00M | $501.00M |
| Gross profit | $720.00M | $798.00M | $785.00M | $589.00M | $607.00M | $713.00M | $684.00M | $519.00M |
| R&D expense | $99.00M | $92.00M | $97.00M | $93.00M | $89.00M | $92.00M | $94.00M | $81.00M |
| SG&A expense | $393.00M | $449.00M | $381.00M | $338.00M | $351.00M | $400.00M | $341.00M | $300.00M |
| Pretax income | $24.00M | $56.00M | $87.00M | -$259.00M | -$50.00M | $25.00M | $60.00M | -$51.00M |
| Income tax | $6.00M | $2.00M | $30.00M | $17.00M | -$16.00M | $14.00M | -$7.00M | -$43.00M |
| Net income | $18.00M | $54.00M | $57.00M | -$276.00M | -$34.00M | $11.00M | $67.00M | -$8.00M |
| EPS (basic) | 0.04 | 0.11 | 0.11 | — | -0.07 | 0.02 | 0.14 | — |
| EPS (diluted) | 0.04 | 0.11 | 0.11 | — | -0.07 | 0.02 | 0.13 | — |
| Weighted avg. shares (diluted) | 506.50M | 505.90M | 506.00M | — | 496.80M | 500.10M | 499.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $465.00M | $530.00M | $428.00M | $545.00M | $505.00M | $539.00M | $487.00M | $468.00M |
| Receivables | $992.00M | $1.08B | $1.08B | $873.00M | $894.00M | $989.00M | $970.00M | $805.00M |
| Inventory | $1.82B | $1.77B | $1.72B | $1.74B | $1.71B | $1.67B | $1.59B | $1.57B |
| Current assets | $3.73B | $3.80B | $3.58B | $3.46B | $3.49B | $3.61B | $3.44B | $3.21B |
| PP&E, net | $1.44B | $1.41B | $1.40B | $1.41B | $1.39B | $1.36B | $1.05B | $993.00M |
| Goodwill | $4.80B | $4.84B | $4.72B | $4.78B | $4.76B | $4.76B | $4.51B | $4.41B |
| Intangibles | $3.03B | $3.20B | $3.23B | $3.41B | $3.60B | $3.71B | $3.63B | $3.68B |
| Total assets | $13.34B | $13.56B | $13.22B | $13.36B | $13.55B | $13.74B | $12.94B | $12.61B |
| Current liabilities | $1.79B | $1.85B | $1.66B | $1.60B | $1.46B | $1.39B | $1.27B | $1.31B |
| Short-term debt | $74.00M | $73.00M | $73.00M | $74.00M | $62.00M | $61.00M | $44.00M | $44.00M |
| Long-term debt | $3.63B | $3.85B | $3.92B | $3.94B | $3.96B | $4.15B | $4.35B | $4.28B |
| Total debt | $3.71B | $3.92B | $3.99B | $4.02B | $4.02B | $4.21B | $4.39B | $4.32B |
| Total liabilities | $6.71B | $6.97B | $6.72B | $6.81B | $6.80B | $6.97B | $6.59B | $6.52B |
| Shareholders' equity | $6.63B | $6.59B | $6.50B | $6.55B | $6.75B | $6.78B | $6.35B | $6.10B |
| Net debt | $3.24B | $3.39B | $3.56B | $3.47B | $3.52B | $3.67B | $3.91B | $3.85B |
| Shares outstanding | 499.73M | 499.55M | 499.38M | 496.98M | 496.83M | 496.65M | 496.46M | 494.45M |
| Cash flow statement | ||||||||
| Operating cash flow | $216.00M | $277.00M | $13.00M | $108.00M | $219.00M | $237.00M | -$4.00M | $177.00M |
| Capital expenditure | $60.00M | $33.00M | $51.00M | $62.00M | $92.00M | $57.00M | $65.00M | $47.00M |
| Free cash flow | $156.00M | $244.00M | -$38.00M | $46.00M | $127.00M | $180.00M | -$69.00M | $130.00M |
| Investing cash flow | -$62.00M | -$110.00M | -$60.00M | -$64.00M | -$101.00M | -$56.00M | -$58.00M | -$90.00M |
| Financing cash flow | -$216.00M | -$74.00M | -$65.00M | -$18.00M | -$153.00M | -$156.00M | $52.00M | -$32.00M |
| Depreciation & amortization | $27.00M | $26.00M | $172.00M | $174.00M | $28.00M | $25.00M | $161.00M | $164.00M |
| Stock-based compensation | $20.00M | $20.00M | $21.00M | $16.00M | $17.00M | $20.00M | $15.00M | $15.00M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.